Tianjin Medical Journal

Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (5): 539-543.doi: 10.11958/20212207

Previous Articles     Next Articles

The clinical efficacy and safety of anlotinib and albumin-bound paclitaxel as the third-line therapy in patients with non-small cell lung cancer cancer

ZHAO Zilong1, ZHANG Meiyun2, GAO Hui2, DU Wei2, BA Yaer2, LYU Yihua2△   

  1. 1 Department of Respiratory and Critical Care, the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014010, China; 2 Department of General Oncology, Baotou Tumor Hospital
  • Received:2021-09-24 Revised:2022-01-09 Published:2022-05-15 Online:2022-07-04

PDF (PC)

2276

Abstract: Objective　To investigate the clinical efficacy and safety of anlotinib and albumin-bound paclitaxel (Nab-P) as the third-line therapy in patients with non-small cell lung cancer (NSCLC). Methods　Seventy-nine patients with NSCLC were included in this study. According to the treatment plan, patients were divided into the control group (36 cases) and the study group (43 cases). The control group was treated with Nab-P, and the study group was treated with anlotinib combined with Nab-P. The clinical efficacy, progression free survival (PFS), overall survival (OS) and adverse reactions were observed in the two groups. The serum levels of vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) were observed before and after treatment in the two groups. Results　There was no significant difference in objective remission rate (ORR) between the two groups (16.28% vs. 8.33%，P＞0.05). The disease control rate (DCR) was significantly higher in the study group than that of the control group (76.74% vs. 52.78%, P＜0.05). The median PFS of the study group and the control group were 4 months and 3 months respectively (P＞0.05), and the median OS of the study group and the control group were 9 months and 7 months respectively (P＜0.05). After treatment, the serum levels of VEGF, CEA and CA125 were decreased than those of before treatment in the two groups (P＜0.05), and the serum levels of VEGF, CEA and CA125 were significantly lower in the study group than those in the control group (P＜0.05). During the treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion　Anlotinib combined with Nab-P as the third-line treatmenthas has good clinical efficacy in patients with NSCLC, which can effectively reduce serum VEGF, CEA and CA125 levels with good safety. 

Key words: albumin-bound paclitaxel, carcinoma, non-small-cell lung, molecular targeted therapy, vascular endothelial growth factors, carcinoembryonic antigen, CA-125 antigen, anlotinib

CLC Number: